WSE:BIO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BIOTON S.A., a biotechnological company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, and other pharmaceutical products in Poland and internationally.


Snowflake Analysis

Adequate balance sheet and fair value.

Share Price & News

How has BIOTON's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BIO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.4%

BIO

-2.5%

PL Biotechs

3.7%

PL Market


1 Year Return

4.4%

BIO

60.2%

PL Biotechs

-16.4%

PL Market

Return vs Industry: BIO underperformed the Polish Biotechs industry which returned 61.1% over the past year.

Return vs Market: BIO exceeded the Polish Market which returned -17.9% over the past year.


Shareholder returns

BIOIndustryMarket
7 Day-2.4%-2.5%3.7%
30 Day16.6%2.6%9.7%
90 Day44.8%52.3%-2.9%
1 Year4.4%4.4%60.5%60.2%-14.4%-16.4%
3 Year-15.6%-15.6%22.6%22.4%-20.5%-26.0%
5 Year-22.4%-22.4%-9.8%-11.6%-16.3%-26.4%

Price Volatility Vs. Market

How volatile is BIOTON's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BIOTON undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BIO (PLN4.43) is trading below our estimate of fair value (PLN16.48)

Significantly Below Fair Value: BIO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BIO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BIO is unprofitable, so we can't compare its PE Ratio to the Polish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BIO is good value based on its PB Ratio (0.6x) compared to the PL Biotechs industry average (5.9x).


Next Steps

Future Growth

How is BIOTON forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

34.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BIOTON has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BIOTON performed over the past 5 years?

30.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIO is currently unprofitable.

Growing Profit Margin: BIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BIO is unprofitable, but has reduced losses over the past 5 years at a rate of 30.4% per year.

Accelerating Growth: Unable to compare BIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.1%).


Return on Equity

High ROE: BIO has a negative Return on Equity (-25.13%), as it is currently unprofitable.


Next Steps

Financial Health

How is BIOTON's financial position?


Financial Position Analysis

Short Term Liabilities: BIO's short term assets (PLN147.9M) do not cover its short term liabilities (PLN168.8M).

Long Term Liabilities: BIO's short term assets (PLN147.9M) exceed its long term liabilities (PLN133.9M).


Debt to Equity History and Analysis

Debt Level: BIO's debt to equity ratio (20.9%) is considered satisfactory.

Reducing Debt: BIO's debt to equity ratio has increased from 11.9% to 20.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable BIO has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: BIO is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 36.9% per year.


Next Steps

Dividend

What is BIOTON's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIO's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average board tenure


CEO

Robert Neymann

3.08yrs

Tenure

Mr. Robert Neymann has been President of the Management Board at BIOTON S.A. since July 4, 2017. Mr. Neymann served as the President of the Management Board at Harper Hygienics S.A., since 2007 until May 1 ...


Board Members

NamePositionTenureCompensationOwnership
Ramesh Rajentheran
Vice President of the Supervisory Boardno datano datano data
Wei Tan
Member of the Supervisory Boardno datano datano data
Nicola Cadei
Member of the Supervisory Boardno datano datano data
Dariusz Trzeciak
Vice-President of Supervisory Board3.08yrsno datano data
Ju Liu
Member of Supervisory Board4.33yrsno datano data
Vaidyanathan Viswanath
Member of Supervisory Board4yrsno datano data
Hao Fan
Chairman of the Supervisory Board0.50yrno datano data

3.5yrs

Average Tenure

46yo

Average Age

Experienced Board: BIO's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BIOTON S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BIOTON S.A.
  • Ticker: BIO
  • Exchange: WSE
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: zł380.378m
  • Shares outstanding: 85.86m
  • Website: https://www.bioton.pl

Number of Employees


Location

  • BIOTON S.A.
  • ul. Poznanska 12
  • Macierzysz
  • Ozarów Mazowiecki
  • 05-850
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOWSE (Warsaw Stock Exchange)YesCommon Bearer SharesPLPLNJul 2005
0DTRLSE (London Stock Exchange)YesCommon Bearer SharesGBPLNJul 2005

Biography

BIOTON S.A., a biotechnological company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, and other pharmaceutical products in Poland and internationally. The company offers recombinant human insulin in pharmaceutical substance form and as preparations for injections; and oral hypoglycemic drugs, including glimepiride and metformin. It also provides FOOT CREAM prodiab that is used for the treatment of dry and atopic skin; HEALTHY EYES prodiab, a dietary supplement for the proper functioning of the eye; Healthy Heart prodiab, a dietary supplement for the proper functioning of the heart and the cardiovascular system; HEALTHY HEART PLUS prodiab, a dietary supplement for the proper functioning of the heart and circulatory system; and VITAMINS AND MINERALS prodiab, a dietary supplement for the cardiovascular system. In addition, the company offers an OTC products line focusing on diet supplements, nutritional uses, and cosmetics for patients with metabolic syndrome and diabetes health problems; and BIOTON FOR HEALTH line of natural ingredients. Further, it is involved in the advertising and advisory activities. The company is based in Ozarów Mazowiecki, Poland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/03 21:40
End of Day Share Price2020/06/03 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.